A Randomized, Open-label, Cross-over Phase 2 Trial of Darolutamide and Enzalutamide in Men with Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer: Patient Preference and Cognitive Function in ODENZA-Reference-Cited by-同舟云学术

A Randomized, Open-label, Cross-over Phase 2 Trial of Darolutamide and Enzalutamide in Men with Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer: Patient Preference and Cognitive Function in ODENZA

Published:2023-06 Issue: Volume: Page:
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Colomba Emeline^ORCID,Jonas Sarah Flora,Eymard Jean-Christophe,Delva Rémi,Brachet Pierre Emmanuel,Neuzillet Yann,Penel Nicolas,Roubaud Guilhem,Bompas Emmanuelle,Mahammedi Hakim,Longo Raffaelle,Helissey Carole,Barthélemy Philippe,Borchiellini Delphine,Hasbini Ali,Priou Franck,Saldana Carolina,Voog Eric,Narcisso Bérangère,Ladoire Sylvain,Berdah Jean-François,Aisenfarb Jean-Baptiste,Foulon Stéphanie,Fizazi Karim

Publisher

Elsevier BV

Subject

Urology

Reference30 articles.

1. Abiraterone and increased survival in metastatic prostate cancer;de Bono;N Engl J Med,2011

2. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer;Fizazi;N Engl J Med,2017

3. Enzalutamide in metastatic prostate cancer before chemotherapy;Beer;N Engl J Med,2014

4. NEJM. Apalutamide for metastatic, castration-sensitive prostate cancer. https://www.nejm.org/doi/full/10.1056/nejmoa1903307.

5. Bayer. Communications BA. Phase III trial with darolutamide in combination with docetaxel and androgen deprivation therapy meets primary endpoint of significantly increasing overall survival in patients with metastatic hormone-sensitive prostate cancer. http://media.bayer.com/baynews/baynews.nsf/id/Phase-III-trial-Nubeqa-darolutamide-combination-docetaxel-androgen-deprivation-therapy-meets-primary.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Short-term Darolutamide (ODM-201) Concomitant to Radiation Therapy for Patients with Unfavorable Intermediate-risk Prostate Cancer: The Darius (AFU-GETUG P15) Phase 2 Trial Protocol;European Urology Oncology;2024-05

2. Patient Preference of Apalutamide Versus Enzalutamide for Recurrent or Metastatic Hormone-sensitive Prostate Cancer: An Open-label, Randomized, Crossover Trial;European Urology Oncology;2024-04

3. Safety profile of darolutamide versus placebo: a systematic review and meta-analysis;Prostate Cancer and Prostatic Diseases;2023-12-14

4. Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer;Prostate Cancer and Prostatic Diseases;2023-10-26

5. New insights into molecular signaling pathways and current advancements in prostate cancer diagnostics & therapeutics;Frontiers in Oncology;2023-08-17